Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

Abstract: A method of inhibiting GAPDH with N-methylol transfer agents and/or related compounds.

Abstract: A method of preventing, inhibiting or reducing cytokine release and the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject with certain oxathiazin-like compounds and/or related compounds.

Abstract: A method of inhibiting GAPDH with certain oxathiazin-like compounds and/or related compounds.

Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Abstract: A method of inducing apoptotic death of a neoplastic cell, whereby the neoplastic cell is contacted with an apoptosis-inducing amount of a methylol-containing compound. This method is useful for treating both primary and metastatic cancers. A preferred embodiment includes administering a methylol transfer agent to the mammal, at a total daily dose of from about 2 g to about 60 g, the administration including at least two dosing cycles, each dosing cycle including an infusion phase of about 1 to 8 days, and a non-administration phase of about 1 to 14 days. Another embodiment includes treating liver cancer by administration of a solution of a methylol transfer agent directly to the liver via a hepatic vessel.

Abstract: Vector constructs and methods for producing non-human transgenic animals comprising within their genome a conditional targeted mutation within the glyt1 gene are provided. These animals can be utilized as a tool for assessing GLYT1 function as well as a model for studying the effects of enhancing synaptic NMDA receptor function. In addition, these animals can be utilized for studying the susceptibility to compounds inducing psychotic behavior.

Abstract: A method of inducing apoptotic death of a neoplastic cell, whereby the neoplastic cell is contacted with an apoptosis-inducing amount of a methylol-containing compound. This method is useful for treating both primary and metastatic cancers. A preferred embodiment includes administering a :4 methylol transfer agent to the mammal, at a total daily dose of from about 2 g to about 60 g, the administration including at least two dosing cycles, each dosing cycle including an infusion phase of about 1 to 8 days, and a non-administration phase of about 1 to 14 days. Another embodiment includes treating liver cancer by administration of a solution of a methylol transfer agent directly to the liver via a hepatic vessel.